AOLS (Aeolus Pharmaceuticals) EBITDA Margin %: -7,300.00% (As of Jun. 2017)


What is Aeolus Pharmaceuticals EBITDA Margin %?

Aeolus Pharmaceuticals AOLS EBITDA Margin % is -7,300.00% as of Jun. 2017.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Aeolus Pharmaceuticals's EBITDA for the three months ended in Jun. 2017 was $-0.95 Mil. Aeolus Pharmaceuticals's Revenue for the three months ended in Jun. 2017 was $0.01 Mil. Therefore, Aeolus Pharmaceuticals's EBITDA margin for the quarter that ended in Jun. 2017 was -7,300.00%.

Aeolus Pharmaceuticals  (OTCPK:AOLS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Aeolus Pharmaceuticals EBITDA Margin % Related Terms

Aeolus Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Aeolus Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals EBITDA Margin % Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -32.41 -68.53 -0.83 -84.41 -157.66

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -132.12 -187.36 -1,309.64 -802.33 -7,300.00

AOLS vs RDGL, PCYN, YBAO: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aeolus Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aeolus Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aeolus Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Aeolus Pharmaceuticals's EBITDA Margin % falls into.


Aeolus Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Aeolus Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Sep. 2016 is calculated as

EBITDA Margin %=EBITDA (A: Sep. 2016 )/Revenue (A: Sep. 2016 )
=-3.273/2.076
=-157.66 %

Aeolus Pharmaceuticals's EBITDA Margin % for the quarter that ended in Jun. 2017 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2017 )/Revenue (Q: Jun. 2017 )
=-0.949/0.013
=-7,300.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -7,300.00% mean?
Aeolus Pharmaceuticals (AOLS) has a EBITDA Margin % of -7,300.00% as of Jun. 2017. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aeolus Pharmaceuticals and its competitors.
Is Aeolus Pharmaceuticals' EBITDA Margin % too high?
Aeolus Pharmaceuticals' current EBITDA Margin % is -7,300.00%.
How does Aeolus Pharmaceuticals' EBITDA Margin % compare to RDGL and PCYN?
Aeolus Pharmaceuticals' EBITDA Margin % of -7,300.00% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aeolus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aeolus Pharmaceuticals's current EBITDA Margin % is -7,300.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aeolus Pharmaceuticals stock overvalued right now?
Aeolus Pharmaceuticals (AOLS) has a current EBITDA Margin % of -7,300.00%. The current EBITDA Margin % is -7,300.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Aeolus Pharmaceuticals (AOLS), the current EBITDA Margin % is -7,300.00% as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aeolus Pharmaceuticals Business Description

Address 26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.